Not Yet RecruitingNot Applicable

Ovarian Reserve in Intensive Care Patients

75 participantsStarted 2025-06-15

Plain-language summary

Gastrointestinal, pulmonary, nephrological, cardiac, neurologic and psychological effects in critically ill patients followed in the intensive care unit have been shown in the literature. However, the effects on ovarian reserve in these patients have not been sufficiently investigated and studies investigating this issue are limited in the literature. The synthesis, release frequency and amplitude of reproductive hormones change under stress. In addition, changes in ovarian homeostasis affect ovarian reserve. The aim of this study was to evaluate ovarian reserve in critically ill patients followed up in the intensive care unit.

Who can participate

Age range

18 Years – 35 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-35 years of age * Female patients followed in the intensive care unit for more than 24 hours for internal or surgical reasons, * Women whose ovarian reserve is being evaluated, Exclusion Criteria: * Previous ovarian surgery, endometriosis, endometrioma, * History of chemotherapy, radiotherapy, * Ovarian cyst, malignancy and other ovarian pathologies, * Women with single ovary, * Women receiving hormone therapy, * Polycystic ovary syndrome, * Surgical intervention within the last 6 months, * History of drug, alcohol, substance use, * Women in pregnancy, puerperium, lactation, * History of vaccination within the last 6 months

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

ovarian follicle count

Timeframe: 24 hour

Trial details

NCT IDNCT06999291

SponsorHaseki Training and Research Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-15

Contact for this trial

emine yılmaz güler

905054525261 dr.emine.yilmaz@gmail.com

View on ClinicalTrials.gov More Anti-Mullerian Hormone Deficiency trials